Marked direct suppression of primary hyperparathyroidism with osteitis fibrosa cystica by intravenous administration of 1,25-dihydroxycholecalciferol.
A marked direct suppression of primary hyperparathyroidism with osteitis fibrosa cystica has been achieved by the intravenous administration of 1,25-dihydroxycholecalciferol [1,25(OH)2D]. In a recent survey of 306 patients with primary hyperparathyroidism (PHPT), we hypothesized that the far higher degree of parathyroid hormone (PTH) hypersecretion in PHPT with osteitis fibrosa cystica than in PHPT without overt bone disease might be due to the absence of suppression of hormonal hypersecretion by the low-to-normal circulating 1,25(OH)2D reflecting a relative vitamin D deficiency. To test this hypothesis, a patient having hypercalcemic PHPT with florid osteitis fibrosa cystica and normal serum 1,25(OH)2D was given increasing daily doses of intravenous calcitriol (0.5-2 micrograms) for several days. Doubling the level of circulating 1,25(OH)2D from 48 to 100-114 pg/ml was accompanied by a marked decline (46%) in serum iPTH(1-84), without a change in the serum calcium concentration. A lowered set point of parathyroid cells for calcium, and a diminished maximum secretory rate of PTH, may contribute to the marked suppression of PHPT.
Patron
P
P
Service d'Exploration Fonctionnelle Métabolique, Université Paris-VII, Hôpital Louis-Mourier, Colombes, France.
Gardin
J P
JP
Borensztein
P
P
Prigent
A
A
Paillard
M
M
D002117:Calcitriol / Q000627:therapeutic use*; D002118:Calcium / Q000008:administration & dosage / Q000097:blood; D005260:Female; D006801:Humans; D006961:Hyperparathyroidism / Q000150:complications / Q000188:drug therapy*; D007275:Injections, Intravenous; D008875:Middle Aged; D010002:Osteitis Fibrosa Cystica / Q000150:complications / Q000188:drug therapy*; D014808:Vitamin D Deficiency / Q000150:complications / Q000188:drug therapy / Q000378:metabolism
D002117:Calcitriol; D002118:Calcium